News

News

December 10, 2007

Immunomedics Epratuzmab plus Rituximab produce durable complete responses in lymphoma

December 10, 2007

Immunomedics develops new interferon product using dock-and-lock

December 10, 2007

Immunomedics reports advances in cancer therapy

December 5, 2007

Immunomedics announces outcome of 2007 annual meeting of shareholders

December 3, 2007

Immunomedics to present at American Society of Hematology 49th annual meeting

November 20, 2007

Immunomedics to present at Lazard Capital Markets fourth annual healthcare conference

November 7, 2007

Immunomedics announces first quarter fiscal 2008 results

October 30, 2007

Immunomedics to present at Acumen Biofin Rodman & Renshaw 9th annual healthcare conference

October 25, 2007

Immunomedics develops two new drug immunoconjugates for targeted therapy of colon and lung cancers

October 24, 2007

Milatuzumab showed promising therapeutic effects alone and combined with CD20 antibody in preclinical studies

October 18, 2007

Immunomedics to present at the AACR-NCI-EORTC international conference

October 16, 2007

Immunomedics awarded U.S. patent for humanized PAM4 monoclonal antibody and its use in the diagnosis and therapy of pancreatic cancer

September 13, 2007

Immunomedics announces fiscal 2007 results

August 16, 2007

Study reports Epratuzumab affects B-cells from patients with lupus in a unique manner

August 7, 2007

Immunomedics appoints Edward T. Wolynic to board of directors

June 13, 2007

Immunomedics set to join Russell 3000 index

June 11, 2007

Fractionated radioimmunotherapy with 90Y-Epratuzumab in non-Hodgkin’s lymphoma appears safe and active in in a phase I/II study

- Results Presented at the 12th Congress of European Hematology Association (EHA) -

June 8, 2007

Immunomedics to present at the sixth annual Needham Biotechnology and Medical Technology Conference

June 5, 2007

Immunomedics reports initial clinical results with hpam4 for pancreatic cancer therapy

- Results Presented at Society of Nuclear Medicine Annual Meeting -

June 4, 2007

Immunomedics reports new and updated clinical results from dose de-escalation study with HA20 in lymphoma patients

- Results Presented at American Society of Clinical Oncology Annual Meeting -

June 4, 2007

Repeated radioimmunotherapy with 131i-labetuzumab appears safe and effective in colorectal cancer with liver metastases

- Initial Phase II Study Results Presented at Society of Nuclear Medicine Annual Meeting -

June 4, 2007

Promising results with Epratuzumab and chemotherapy in children with acute lymphoblastic leukemia

- Results from a Children’s Oncology Group (COG) Study Presented at American Society of Clinical Oncology Annual Meeting

May 30, 2007

Immunomedics to present at the Society of Nuclear Medicine 54th annual meeting

May 29, 2007

Promising results with Epratuzumab and chemotherapy in children with acute lymphoblastic leukemia

May 10, 2007

Immunomedics to present at acumen biofin rodman & renshaw 4th annual Global Healthcare Conference

May 8, 2007

Immunomedics announces third quarter fiscal 2007 results

May 7, 2007

Immunomedics completes $24 million registered direct offering of common stock

May 2, 2007

Immunomedics to raise gross proceeds of $24 million in registered direct offering of common stock

April 17, 2007

Immunomedics develops novel immunotoxin for therapy of prostate and lung cancers

April 17, 2007

Early stage pancreatic cancer expresses antigen targeted by PAM4 antibodyimmunomedics

- Results Suggest PAM4 Can Be Developed For Early Detection of Pancreatic Cancer -

February 9, 2007

Immunomedics announces second quarter fiscal 2007 results

January 10, 2007

Immunomedics mourns the loss of board member Richard Pivirotto